178 related articles for article (PubMed ID: 18950770)
1. ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Deckers JW; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R
Atherosclerosis; 2009 May; 204(1):273-5. PubMed ID: 18950770
[TBL] [Abstract][Full Text] [Related]
2. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators
Cardiovasc Drugs Ther; 2003 Jan; 17(1):83-91. PubMed ID: 12843690
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
5. Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure.
Krysiak R; Okopień B
Pharmacol Rep; 2012; 64(6):1466-75. PubMed ID: 23406757
[TBL] [Abstract][Full Text] [Related]
6. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
7. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
8. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
9. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease.
Musicant SE; Taylor LM; Peters D; Schuff RA; Urankar R; Landry GJ; Moneta GL
J Vasc Surg; 2006 Apr; 43(4):772-80; discussion 780. PubMed ID: 16616235
[TBL] [Abstract][Full Text] [Related]
11. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
12. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
13. Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation.
Lim HS; Schultz C; Dang J; Alasady M; Lau DH; Brooks AG; Wong CX; Roberts-Thomson KC; Young GD; Worthley MI; Sanders P; Willoughby SR
Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):83-9. PubMed ID: 24446024
[TBL] [Abstract][Full Text] [Related]
14. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome.
Kilic T; Oner G; Ural E; Yumuk Z; Sahin T; Bildirici U; Acar E; Celikyurt U; Kozdag G; Ural D
Atherosclerosis; 2009 Dec; 207(2):552-8. PubMed ID: 19523634
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients.
Lee BJ; Lin JS; Lin YC; Lin PT
Nutrition; 2015 Mar; 31(3):475-9. PubMed ID: 25701337
[TBL] [Abstract][Full Text] [Related]
17. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
[TBL] [Abstract][Full Text] [Related]
18. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
[TBL] [Abstract][Full Text] [Related]
19. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
[TBL] [Abstract][Full Text] [Related]
20. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Morange PE; Bickel C; Nicaud V; Schnabel R; Rupprecht HJ; Peetz D; Lackner KJ; Cambien F; Blankenberg S; Tiret L;
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2793-9. PubMed ID: 17023678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
